Solid Biosciences Inc (SLDB)
8.25
+0.61
(+7.98%)
USD |
NASDAQ |
May 31, 16:00
8.22
-0.03
(-0.36%)
After-Hours: 20:00
Solid Biosciences Research and Development Expense (Annual): 76.56M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 76.56M |
| December 31, 2022 | 78.42M |
| December 31, 2021 | 58.74M |
| December 31, 2020 | 64.88M |
| December 31, 2019 | 94.74M |
| Date | Value |
|---|---|
| December 31, 2018 | 57.96M |
| December 31, 2017 | 39.90M |
| December 31, 2016 | 20.12M |
| December 31, 2015 | 4.192M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
58.74M
Minimum
2021
94.74M
Maximum
2019
74.67M
Average
76.56M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics Inc | 877.39M |
| PTC Therapeutics Inc | 666.56M |
| Capricor Therapeutics Inc | 36.45M |
| Catalyst Pharmaceuticals Inc | 93.15M |
| Pfizer Inc | 10.68B |